<code id='8509822AEF'></code><style id='8509822AEF'></style>
    • <acronym id='8509822AEF'></acronym>
      <center id='8509822AEF'><center id='8509822AEF'><tfoot id='8509822AEF'></tfoot></center><abbr id='8509822AEF'><dir id='8509822AEF'><tfoot id='8509822AEF'></tfoot><noframes id='8509822AEF'>

    • <optgroup id='8509822AEF'><strike id='8509822AEF'><sup id='8509822AEF'></sup></strike><code id='8509822AEF'></code></optgroup>
        1. <b id='8509822AEF'><label id='8509822AEF'><select id='8509822AEF'><dt id='8509822AEF'><span id='8509822AEF'></span></dt></select></label></b><u id='8509822AEF'></u>
          <i id='8509822AEF'><strike id='8509822AEF'><tt id='8509822AEF'><pre id='8509822AEF'></pre></tt></strike></i>

          explore

          explore

          author:fashion    Page View:66
          NASDAQ
          Spencer Platt/Getty Images

          Emergent BioSolutions, the manufacturing company that fell into hot water in 2021 due to a contamination issue involving millions of doses of Covid vaccines, is pivoting its business and cutting hundreds of jobs, including a C-suite role.

          The company announced Tuesday that it will cut 400 jobs and eliminate the role of chief operating officer as part of a shift away from its contract manufacturing services business. The current chief operating officer, Adam Havey, will leave the company on Sept. 30.

          advertisement

          Instead, Emergent will focus on producing Narcan nasal spray and other products. The overdose reversal medicine became available as an over-the-counter medicine earlier this year.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK
          JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

          InhonorofJPMWeek,you’rereadingaspecialeditionofourbiotechnewsletter,TheReadout.Tostayontopofthelates

          read more
          Apple is now the first public company to be valued at $3 trillion
          Apple is now the first public company to be valued at $3 trillion

          6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

          read more

          Drug for rare kidney disease narrowly misses mark in clinical trial

          AdobeTravereTherapeuticssaidThursdaythatastudymeanttoconfirmthebenefitofitsnewlyapproveddrugforarare